Onconova Therapeutics, Inc. Contracts & Agreements
97 Contracts & Agreements
- Business Finance (63 contracts)
- Business Operations (5)
- Human Resources (19)
- Intellectual Property (3)
- Uncategorized (7)
- Employment Agreement by and between the Company and Victor Mandia Moyo, MBChB., dated as of October 2, 2023 (Filed With SEC on November 14, 2023)
- Onconova Therapeutics, Inc. 2021 Incentive Compensation Plan, as Amended and Restated, as approved by stockholders (Filed With SEC on November 14, 2022)
- Employment Agreement Amendment between Onconova Therapeutics, Inc. and Mark Guerin dated June 10, 2022 (Filed With SEC on June 13, 2022)
- Form of Restricted Stock Unit Agreement (Filed With SEC on November 15, 2021)
- Form of Non-Qualified Stock Option Agreement (Filed With SEC on November 15, 2021)
- Underwriting Agreement, dated September 23, 2021, by and between Onconova Therapeutics, Inc. and Guggenheim Securities, LLC (Filed With SEC on September 24, 2021)
- Equity Distribution Agreement, dated as of August 20, 2021, between Onconova Therapeutics, Inc. and Piper Sandler & Co (Filed With SEC on August 20, 2021)
- Employment Agreement, dated June 14, 2021, by and between Onconova Therapeutics, Inc. and Mark Stephen Gelder,M.D (Filed With SEC on August 16, 2021)
- Employment Agreement, dated March 9, 2021, by and between Onconova Therapeutics, Inc. and Abraham N. Oler (Filed With SEC on August 16, 2021)
- Amendment to Employment Agreement, dated as of March 18, 2021, by and between Onconova Therapeutics, Inc. and Steven M. Fruchtman, M.D (Filed With SEC on March 18, 2021)
- Underwriting Agreement, dated February 10, 2021, by and between Onconova Therapeutics, Inc. and Guggenheim Securities, LLC (Filed With SEC on February 12, 2021)
- Form of Purchase Agreement, dated as of January 7, 2021, by and among Onconova Therapeutics, Inc. and the investors party thereto (Filed With SEC on January 8, 2021)
- Form of Stock Appreciation Right Award Agreement (for Non-Employee Directors) (Filed With SEC on November 16, 2020)
- Form of Stock Appreciation Right Award Agreement (Filed With SEC on July 10, 2020)
- Form of Performance Stock Unit Award Agreement (Filed With SEC on July 10, 2020)
- Description of the Company's Securities Registered under Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 27, 2020)
- Form of Placement Agent Warrant (Filed With SEC on January 3, 2020)
- Form of Securities Purchase Agreement, dated as of December 31, 2019, among Onconova Therapeutics, Inc. and the Purchasers named therein (Filed With SEC on January 3, 2020)
- Distribution, License and Supply Agreement, dated as of December 18, 2019, by and between Onconova Therapeutics, Inc. and Specialised Therapeutics Asia Pte. Ltd (Filed With SEC on December 19, 2019)
- Form of Investor Warrant (Filed With SEC on December 19, 2019)
- Form of Placement Agent Warrant (Filed With SEC on December 19, 2019)
- Form of Securities Purchase Agreement, dated as of December 17, 2019, among Onconova Therapeutics, Inc. and the Purchasers named therein (Filed With SEC on December 19, 2019)
- Form of Investor Warrant (Filed With SEC on December 10, 2019)
- Form of Securities Purchase Agreement, dated as of December 6, 2019, among Onconova Therapeutics, Inc. and the Purchasers named therein (Filed With SEC on December 10, 2019)
- Form of Placement Agent Warrant (Filed With SEC on December 10, 2019)
- Form of Securities Purchase Agreement, dated as of November 21, 2019, among Onconova Therapeutics, Inc. and the Purchasers named therein (Filed With SEC on November 26, 2019)
- Form of Common Warrant (Filed With SEC on November 26, 2019)
- Form of Pre-Funded Warrant (Filed With SEC on November 26, 2019)
- Form of Placement Agent Warrant (Filed With SEC on November 26, 2019)
- Distribution, License and Supply Agreement, dated as of November 20, 2019, by and between Onconova Therapeutics, Inc. and Knight Therapeutics Inc (Filed With SEC on November 21, 2019)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 14, 2019)
- Form of Placement Agent Warrant (Filed With SEC on November 14, 2019)
- Form of Pre-Funded Warrant (Filed With SEC on November 14, 2019)
- Form of Warrant (Filed With SEC on November 14, 2019)
- Form of Underwriter Warrant (Filed With SEC on November 12, 2019)
- Form of Amendment to Warrant, dated as of September 23, 2019 (Filed With SEC on November 12, 2019)
- Form of Pre-Funded Warrant (Filed With SEC on November 12, 2019)
- Form of Warrant (Filed With SEC on November 12, 2019)
- Form of Underwriting Agreement (Filed With SEC on November 12, 2019)
- Form of Placement Agent Warrant (Filed With SEC on September 25, 2019)
- Form of Securities Purchase Agreement, dated as of September 23, 2019, among Onconova Therapeutics, Inc. and the Purchasers named therein (Filed With SEC on September 25, 2019)
- Securities Purchase Agreement, dated as of May 10, 2019, by and between Onconova Therapeutics, Inc. and HanX Biopharmaceuticals, Inc (Filed With SEC on August 14, 2019)
- Securities Purchase Agreement, dated as of May 10, 2019, by and between Onconova Therapeutics, Inc. and Abundant New Investments Ltd (Filed With SEC on August 14, 2019)
- License and Collaboration Agreement, dated as of May 10, 2019, by and between Onconova Therapeutics, Inc. and HanX Biopharmaceuticals, Inc (Filed With SEC on August 14, 2019)
- Sales Agreement, dated May 17, 2019, by and between Onconova Therapeutics, Inc. and Roth Capital Partners, LLC (Filed With SEC on May 17, 2019)
- Separation and Release Agreement, effective as of January 15, 2019, by and between Onconova Therapeutics, Inc. and Ramesh Kumar, Ph.D (Filed With SEC on January 15, 2019)
- Employment Agreement, effective as of November 5, 2018, by and between the Company and Richard C. Woodman, M.D (Filed With SEC on November 14, 2018)
- First Amendment to Underwriter Series A Convertible Preferred Stock Purchase Warrant, dated as of September 24, 2018 (Filed With SEC on November 14, 2018)
- Amended and Restated Employment Agreement, effective as of June 19, 2018, by and between the Company and Steven M. Fruchtman, M.D (Filed With SEC on August 14, 2018)
- Form of Nonqualified Stock Option Award Agreement under the Onconova Therapeutics, Inc. 2018 Omnibus Incentive Compensation Plan (Filed With SEC on July 30, 2018)
- Onconova Therapeutics, Inc. 2018 Omnibus Incentive Compensation Plan (Filed With SEC on June 29, 2018)
- Securities Purchase Agreement, dated as of March 2, 2018, by and between Onconova Therapeutics, Inc. and Pint Pharma GmbH (Filed With SEC on May 15, 2018)
- License, Development and Commercialization Agreement, dated as of March 2, 2018, by and between Onconova Therapeutics, Inc. and Pint International SA (Filed With SEC on May 15, 2018)
- Underwriting Agreement, dated as of April 27, 2018 (Filed With SEC on April 30, 2018)
- Form of Pre-Funded Warrant (Filed With SEC on April 30, 2018)
- Form of Preferred Stock Warrant (Filed With SEC on April 30, 2018)
- Form of Lock-Up Waiver Agreement (Filed With SEC on April 30, 2018)
- Form of Underwriting Agreement (Filed With SEC on April 26, 2018)
- Form of Warrant (Filed With SEC on April 25, 2018)
- Form of Pre-Funded Warrant (Filed With SEC on April 25, 2018)
- Form of Underwriting Agreement (Filed With SEC on April 25, 2018)
- Underwriting Agreement, dated as of February 8, 2018 (Filed With SEC on February 8, 2018)
- Form of Pre-Funded Warrant (Filed With SEC on February 8, 2018)
- Form of Preferred Stock Warrant (Filed With SEC on February 8, 2018)
- Form of Underwriter Warrant (Filed With SEC on February 8, 2018)
- Form of Underwriting Agreement (Filed With SEC on February 7, 2018)
- Form of Underwriter Warrant (Filed With SEC on February 7, 2018)
- Form of Pre-Funded Warrants (Filed With SEC on February 7, 2018)
- Form of Warrants (Filed With SEC on February 7, 2018)
- Placement Agency Agreement, dated as of November 9, 2017 (Filed With SEC on November 13, 2017)
- 2,476,190 Shares ONCONOVA THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 24, 2017)
- www.onconova.com (Filed With SEC on March 29, 2017)
- ONCONOVA THERAPEUTICS, INC. Shares of Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement (Filed With SEC on December 5, 2016)
- ONCONOVA THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on August 15, 2016)
- [FORM OF WARRANT CERTIFICATE] (Filed With SEC on August 15, 2016)
- WARRANT AGREEMENT (Filed With SEC on August 15, 2016)
- ONCONOVA THERAPEUTICS, INC. DEALER-MANAGER AGREEMENT July 7, 2016 (Filed With SEC on July 13, 2016)
- FORM OF WARRANT CERTIFICATE (Filed With SEC on July 1, 2016)
- FORM OF WARRANT AGREEMENT (Filed With SEC on July 1, 2016)
- ONCONOVA THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on July 1, 2016)
- ONCONOVA THERAPEUTICS, INC. DEALER-MANAGER AGREEMENT , 2016 (Filed With SEC on June 29, 2016)
- EMPLOYMENT AGREEMENT (Filed With SEC on February 17, 2016)
- COMMON STOCK PURCHASE WARRANT ONCONOVA THERAPEUTICS, INC. (Filed With SEC on January 6, 2016)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on January 6, 2016)
- ONCONOVA THERAPEUTICS, INC. CONTROLLED EQUITY OFFERINGSM TERMINATION OF SALES AGREEMENT (Filed With SEC on January 6, 2016)
- PURCHASE AGREEMENT (Filed With SEC on October 8, 2015)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 8, 2015)
- ONCONOVA THERAPEUTICS, INC. CONTROLLED EQUITY OFFERINGSM AMENDMENT NO. 1 TO SALES AGREEMENT (Filed With SEC on October 5, 2015)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on August 13, 2015)
- EMPLOYMENT AGREEMENT (Filed With SEC on July 8, 2015)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on July 8, 2015)
- EMPLOYMENT AGREEMENT (Filed With SEC on July 8, 2015)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on July 8, 2015)
- 375 Pheasant Run, Newtown, PA 18940Phone: 267 ###-###-#### Fax: 267 ###-###-#### EMPLOYMENT AGREEMENT (Filed With SEC on March 30, 2015)
- Onconova Therapeutics, Inc. Shares (1) Common Stock ($0.01 par value) Underwriting Agreement (Filed With SEC on July 18, 2013)
- CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on July 18, 2013)
- CONFIDENTIAL (Filed With SEC on July 18, 2013)